New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days

KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more than 82,000 high-risk patients with recent acute coronary syndrome (ACS). The...

from PR Newswire: https://ift.tt/3tW33LA